Navigation Links
Patient-Centric Technology for Better Trial Outcomes, a New and Upcoming Clinical Trial Webinar Hosted by Xtalks
Date:12/4/2013

Toronto, Canada (PRWEB) December 04, 2013

Mobile technology is having an ever growing presence on everyday life as witnessed by the addiction to smart phones and other devices. This technology is now being heavily leveraged along with mHealth applications across all areas of pharmaceutical development. During this webinar, the presenters will explore how mHealth technology can be used to reduce overall clinical development cost, while increasing subject and investigator satisfaction, retention, and engagement.

The goal of the webinar is to broaden the discussion and share ideas. The presenters believe that transformational collaboration is the key to driving better trial outcomes as well as patient outcomes. The use of Patient-Centric Technology highlights these types of collaborations and the speakers will be sharing their experience. The webinar discussion will help viewers:

  • Gain perspective from the speakers on Innovation and Collaboration – both disruptive and sustaining
  • Explore how real-time patient data from devices can be linked to the electronic clinical trial database (EDC systems) through a secure cloud infrastructure today
  • Learn more about an ongoing pilot study to determine if proactive patient engagement can be achieved with targeted interventions based on real-time information
  • Explore mHealth options available today that you viewers can leverage for their next study

For more information on this webinar or to register, visit: http://xtalks.com/Patient-Centric-Technology-for-Better-Trial-Outcom.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year thousands of industry practitioners (from ph
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
2. Positive Clinical Study Results for BSPs HyperQ Technology
3. Arizona State University engineers aim to improve performance of technology in extreme environments
4. iBioLaunch™ Technology Successfully Applied to Modified C1 Inhibitor
5. Pitt discoveries in quantum physics could change face of technology
6. Verenium to Present at Baird Clean Technology Conference
7. Puma Biotechnology Announces Completion of Private Placement
8. Roche NimbleGen and BGI Develop Advanced MHC Region Capture Technology for Human Disease and Biomedical Research
9. Animal Biotechnology - Technologies, Markets and Companies
10. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
11. Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Look inside the new Preferred Solutions® ... lab, from fluid handling to instruments to supplies. Many ... you order. , Preferred Solutions features a full ... L/S® model for precise flow control and dispensing to ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... 15, 2014 The Microcompetition with Foreign DNA ... One of these latent viruses is the Epstein Barr Virus ... Rheumatoid arthritis (RA) is a chronic inflammatory disease that destroys ... found that RA patients have high concentrations of EBV DNA ...
(Date:1/15/2014)... Toronto, ON (PRWEB) January 15, 2014 ... an experimental new therapy for the treatment of tinnitus. ... unique tinnitus frequency, and over a period of weeks to ... Notched Sound Therapy in two forms: Notched Music and Notched ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... ICLL) today announced that the Australian Therapeutic Goods,Administration ... to,prevent Japanese Encephalitis. This final decision step for ... Australian Drug Evaluation,Committee (ADEC) in December 2008. , ... Australian authorities represents the first,regulatory approval for the ...
... Aerolase Corporation, a leading manufacturer of next-generation portable ... sales increased dramatically in 2008 over 2007. The ... market helped to more than offset current economic ... record sales month for Aerolase, and 2008 overall ...
... Jan. 23 Peter T. Wilderotter, president and CEO ... following statement today in response to FDA clearance of ... is an exciting first step for Geron and for ... to advances in medical research. There has been so ...
Cached Biology Technology:Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 2Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 3Australian Authorities (TGA) First to Grant Final Product Approval for Intercell's Vaccine to Prevent Japanese Encephalitis 4Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 2Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers 3Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial 2
(Date:4/17/2014)... German . ... also provide us with a continuous stream of information about ... sit still in a car the world glides by ... Seemingly without effort, our brain calculates self-motion from this "optic ... a steady gaze during our own movements. Together with biologists ...
(Date:4/17/2014)... available in German . ... protection money demanded of him, he can expect his premises ... as fear of the consequences is enough to make restaurant ... birds, which lay their eggs in other birds, nests. If ... parasites take their revenge by destroying the entire nest. Consequently, ...
(Date:4/17/2014)... painted a stark warning on the possible effects of ... effect 32 times that of carbon dioxide. Now a ... act as fully regenerable electron acceptors which helps explain ... instead of being released to the atmosphere. However, there ... may enter into a vicious cycle to release large ...
Breaking Biology News(10 mins):How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Methane climate change risk suggested by proof of redox cycling of humic substances 2
... , Simon Fraser University virologist Masahiro Niikura and his doctoral ... that has discovered a new class of molecular compounds capable ... premise that too much of a good thing can be ... manipulating an enzyme that is key to how influenza replicates ...
... specialists at Florida Hospital Pepin Heart Institute and Dr. Kiran ... Florida announced they have enrolled their first patients into a ... of heart failure after ischemic injury. The therapy may ... to deploy more stem cells to the injury site. ...
... THAN SOUM, LAO PDR (February 21, 2012) The Wildlife ... endangered baby Siamese crocodiles into a local wetland in Lao ... The 19-month-old hatchlings, approximately 70 cm (27 inches) in length, ... at the Lao Zoo for eventual release into their native ...
Cached Biology News:Influenza study: Meet virus' new enemy 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 319 baby Siamese crocs released in Laos 2
Rabbit polyclonal to Lck (phospho Y192) ( Abpromise for all tested applications). entrezGeneID: 3932 SwissProtID: P06239...
Goat polyclonal to Ephrin B2 ( Abpromise for all tested applications). entrezGeneID: 1948 SwissProtID: P52799...
Mouse monoclonal [RL13] to LAP1 ( Abpromise for all tested applications). SwissProtID: Q96NW7...
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
Biology Products: